1. Home
  2. CTW vs CRDL Comparison

CTW vs CRDL Comparison

Compare CTW & CRDL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

CTW

CTW Cayman Class A Ordinary Shares

HOLD

Current Price

$2.66

Market Cap

171.6M

Sector

Technology

ML Signal

HOLD

Logo Cardiol Therapeutics Inc.

CRDL

Cardiol Therapeutics Inc.

HOLD

Current Price

$1.31

Market Cap

154.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CTW
CRDL
Founded
2013
2017
Country
Japan
Canada
Employees
N/A
N/A
Industry
EDP Services
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
171.6M
154.1M
IPO Year
N/A
2017

Fundamental Metrics

Financial Performance
Metric
CTW
CRDL
Price
$2.66
$1.31
Analyst Decision
Strong Buy
Analyst Count
0
2
Target Price
N/A
$8.50
AVG Volume (30 Days)
35.0K
653.6K
Earning Date
05-13-2026
05-14-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$22.41
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.10
$0.88
52 Week High
$3.14
$1.71

Technical Indicators

Market Signals
Indicator
CTW
CRDL
Relative Strength Index (RSI) 60.51 49.10
Support Level $1.88 $0.95
Resistance Level $3.09 $1.43
Average True Range (ATR) 0.26 0.10
MACD -0.00 -0.02
Stochastic Oscillator 69.68 12.50

Price Performance

Historical Comparison
CTW
CRDL

About CTW CTW Cayman Class A Ordinary Shares

CTW Cayman operates the web-based HTML5 gaming platform G123.jp, offering free-to-play games based on Japanese animations, including Queen's Blade, So I'm a Spider, So What?, and Goblin Slayer. The platform features 29 games, with 11 in pre-registration. The Group provides a platform for game developers to generate revenue and reach an international audience through shared revenue from players' in-game purchases. It operates in Japan, Singapore, Taiwan, and China, excluding Taiwan, with the majority of revenue derived from Japan, and has one reporting segment focused on game distribution and related services.

About CRDL Cardiol Therapeutics Inc.

Cardiol Therapeutics Inc is a late-stage life sciences company focused on advancing the development of anti-inflammatory and anti-fibrotic therapies for heart disease. Its primary small-molecule candidate, CardiolRx, targets inflammasome pathway activation, which is involved in the development of inflammation and fibrosis in conditions such as pericarditis, myocarditis, and heart failure. The CardiolRx program includes the completed Phase II MAVERIC-Pilot study and the ongoing Phase III MAVERIC trial for the treatment of pericarditis. The ARCHER program evaluated CardiolRx in acute myocarditis through a completed Phase II study. The company is also developing CRD-38, a novel subcutaneous drug formulation for treating inflammatory heart conditions, including heart failure.

Share on Social Networks: